ClinicalTrials.gg
CompletedNCT07374120Updated Feb 2, 2026

Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

An observational study in Leukemia, Myeloid, Chronic-Phase, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,480
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Chronic-Phase · Novartis.

Started
2024
the only one that year
Observational
4 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, this one is the only one that started in 2024, is one of 4 observational ones, and was the 13th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

2 of the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 21 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 14 (67%) set no upper age limit and 5 (24%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, or all of them as a file.
02

Study summary

This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices.

Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.

03

Conditions studied

  • Leukemia, Myeloid, Chronic-Phase

Keywords

  • CML
  • Tyrosine kinase inhibitors
  • Treatment patterns
  • Real-world
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This was a retrospective, noninterventional cohort study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients whose data were accessible for research purposes during the study observation period.
  2. Patients diagnosed with CML-CP at first recorded diagnosis of CML.
  3. Patients ≥ 18 years of age at first recorded diagnosis of CML.
  4. Patients who initiated qualifying 1L therapy for CML-CP during the study identification period. Qualifying 1L therapy treatments consisted of imatinib, dasatinib, bosutinib, or nilotinib as monotherapy.
  5. Patients with ≥1 visit within The US Oncology Network practices following initiation of 1L therapy and through the end of the study observation period.

Exclusion criteria

Exclusion criteria:

  1. Patients enrolled in interventional clinical trials during the study observation period.
  2. Patients who received any systemic treatment indicated for another primary cancer during the study observation period.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,480 participants (actual)
Patient registry
No

Groups and cohorts

  • CML-CP Group

    Patients with a diagnosis of CML-CP who initiated 1L TKI treatment in The US Oncology Network practices between 01 January 2016 and 31 December 2022.

06

What researchers measure

Primary outcomes

  1. Time From Initial CML Diagnosis to Initiation of 1L TKI Treatment

    Time frame: Baseline

  2. Number of Patients who Received a Stem Cell Transplant (SCT)

    Time frame: Up to approximately 7 years

  3. Number of Patients by Type of 1L and Second-line (2L) TKI Treatment

    Time frame: Up to approximately 7 years

  4. Number of Patients by Initial Dose of Each TKI in 1L and 2L Treatment

    Time frame: Up to approximately 7 years

  5. Number of Patients by Treatment Sequence From 1L TKI to 2L TKI Treatment

    Time frame: Up to approximately 7 years

  6. Number of Patients by Dose Modification of 1L and 2L TKI Treatment

    Dose modifications included dose escalation, reduction, or hold.

    Time frame: Up to approximately 7 years

  7. Number of Patients by Reason for Dose Modification of 1L and 2L TKI Treatment

    Dose modifications included dose escalation, reduction, or hold.

    Time frame: Up to approximately 7 years

  8. Number of Patients who Discontinued 1L and 2L TKI Treatment

    Time frame: Up to approximately 7 years

  9. Number of Patients by Reason for Discontinuing 1L and 2L TKI Treatment

    Time frame: Up to approximately 7 years

  10. Number of Patients by Clinical Events of Interest During 1L and 2L TKI Treatment

    Clinical events of interest included: * Alopecia * Anemia * Arthralgia/Myalgia * Diarrhea * Elevated liver enzyme * Elevated serum creatinine * Fatigue * Febrile neutropenia * Infection secondary to neutropenia * Interstitial lung disease-like events * Leukopenia * Nausea * Neutropenia * Pain * Prolongation of QT interval * Thrombocytopenia * Venous embolism (including pulmonary embolism and/or deep vein thrombosis) * Vomiting

    Time frame: Up to approximately 7 years

  11. Number of Patients by Best Overall Molecular Response (MR) Achieved During 1L and 2L TKI Treatment

    MR was based on BCR::ABL (International Scale \[IS\]) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented

    Time frame: Up to approximately 7 years

  12. Number of Patients by Best Overall MR Achieved Within 12 Months of Initiating 1L and 2L TKI Treatment

    MR was based on BCR::ABL (IS) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented

    Time frame: From Baseline up to 12 months

  13. Number of Patients by MR Achieved After Initiating 1L and 2L TKI Treatment

    MR was based on BCR::ABL (IS) qPCR testing results. Molecular response was categorized as: * MR 2: if BCR::ABL (IS) \>0.1% - ≤ 1% * Major MR (MMR)/MR 3: if BCR::ABL(IS) \>0.01% - ≤0.1% * MR 4: if BCR::ABL1 (IS) \>0.0032% -≤0.01% * MR 4.5: if BCR::ABL (IS) ≤0.0032% * Not documented

    Time frame: 6, 12, 18, and 24 months

  14. Number of Patients who Achieved a BCR::ABL (IS) Result ≤10% Within 6 Months of Initiating 1L and 2L TKI Treatment

    Time frame: From Baseline up to 6 months

  15. Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result <1% Between 6 and 12 Months After Initiating 1L and 2L TKI Treatment

    Time frame: From Month 6 to Month 12

  16. Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result ≤0.1% Between 13 and 24 Months After Initiating 1L and 2L TKI Treatment

    Time frame: From Month 13 to Month 24

  17. Number of Patients who Achieved or Sustained a BCR::ABL (IS) Result ≤0.1% After 24 Months Following Initiating 1L and 2L TKI Treatment

    Time frame: From Month 24 to end of study, up to approximately 6 years

  18. Number of Patients who Achieved Complete Hematologic Response (CHR) During 1L and 2L TKI Treatment

    CHR was observed when white blood cells, hemoglobin, and platelet counts were all within each respective normal lab range.

    Time frame: Up to approximately 7 years

  19. Number of Patients who Achieved CHR Within 12 Months of Initiating 1L and 2L TKI Treatment

    CHR was observed when white blood cells, hemoglobin, and platelet counts were all within each respective normal lab range.

    Time frame: From Baseline up to 12 months

  20. Number of Patients who Achieved Complete Cytogenetic Response (CCyR) During 1L and 2L TKI Treatment

    Cytogenetic response was based on the Philadelphia chromosome results. CCyR was defined as having no Philadelphia chromosome-positive metaphases.

    Time frame: Up to approximately 7 years

  21. Number of Patients who Achieved CCyR Within 12 Months of Initiating 1L and 2L TKI Treatment

    Cytogenetic response was based on the Philadelphia chromosome results. CCyR was defined as having no Philadelphia chromosome-positive metaphases.

    Time frame: From Baseline up to 12 months

  22. Duration of Therapy (DOT) for 1L TKI Treatment

    DOT was defined as the interval between the start date of the 1L therapy (index date) and the end date of 1L therapy, including any treatment interruptions or other breaks.

    Time frame: Up to approximately 7 years

  23. DOT for 2L TKI Treatment

    DOT was defined as the interval between the start date of the 2L therapy and the end date of 2L therapy, including any treatment interruptions or other breaks.

    Time frame: Up to approximately 7 years

  24. Progression-free Survival (PFS) for 1L TKI Treatment

    PFS was defined as physician-documented progression, loss of MR2, BCR::ABL (IS) ≤1%, or an increase in BCR::ABL1 transcript to \>1%, or a 1-log increase in BCR::ABL1 transcript levels with loss of MMR.

    Time frame: Up to approximately 7 years

  25. PFS for 2L TKI Treatment

    PFS was defined as physician-documented progression, loss of MR2, BCR::ABL (IS) ≤1%, or an increase in BCR::ABL1 transcript to \>1%, or a 1-log increase in BCR::ABL1 transcript levels with loss of MMR.

    Time frame: Up to approximately 7 years

  26. Overall Survival (OS) for 1L TKI Treatment

    OS was defined as the interval between the start date of 1L therapy (index date) and the date of death (any cause).

    Time frame: Up to approximately 7 years

  27. Overall Survival (OS) for 2L TKI Treatment

    OS was defined as the interval between the start date of 2L therapy and the date of death (any cause).

    Time frame: Up to approximately 7 years

  28. Treatment-free Interval (TFI)

    TFI was defined as the interval between the discontinuation date of 1L therapy and the start date of 2L therapy or date of death.

    Time frame: Up to approximately 7 years

Secondary outcomes

  1. Number of Patients With BCR::ABL Testing (per National Comprehensive Cancer Network (NCCN) Guidelines) at Diagnosis

    Time frame: Baseline

  2. Number of Patients With BCR::ABL Testing (per NCCN Guidelines) in 3-Month Intervals After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤1% was Achieved

    Time frame: Up to approximately 7 years

  3. After Initiation of 1L and 2L TKI Treatment, Number of Patients With BCR::ABL Testing (per NCCN Guidelines) in 3-Month Intervals Within 2 Years After BCR::ABL1 ≤1% was Achieved

    Time frame: 2 years

  4. After Initiation of 1L and 2L TKI Treatment, Number of Patients With BCR::ABL Testing (per NCCN Guidelines) Between 1 and 3 Months Following 2 Years After BCR::ABL1 ≤1% was Achieved

    Time frame: Up to approximately 5 years

  5. Number of BCR::ABL Tests (per NCCN Guidelines) After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤1% was Achieved

    Time frame: Up to approximately 7 years

  6. Following Initiation of 1L and 2L TKI Treatment, Number of BCR::ABL Tests (per NCCN Guidelines) Within 2 Years After Achieving BCR::ABL1 ≤1%

    Time frame: 2 years

  7. Following Initiation of 1L and 2L TKI Treatment, Number of BCR::ABL Tests (per NCCN Guidelines) Performed After 2 Years of Achieving BCR::ABL1 ≤1%

    Time frame: Up to approximately 5 years

  8. Number of Patients With BCR::ABL Testing (per European LeukemiaNet (ELN) Guidelines) at Diagnosis

    Time frame: Baseline

  9. Number of Patients With BCR::ABL Testing (per ELN Guidelines) in 3-Month Intervals After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤0.1% was Achieved

    Time frame: Up to approximately 7 years

  10. Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 1L Until BCR::ABL1 ≤0.1% was Achieved and Tested Between 2 to 6 Months Until CCyR was Achieved

    Time frame: 5 months

  11. Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 2L Until BCR::ABL1 ≤0.1% was Achieved and Tested Between 2 to 6 Months Until CCyR was Achieved

    Time frame: 5 months

  12. Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 1L Until BCR::ABL1 ≤0.1% was Achieved and Tested Every 12 Months Until CCyR was Achieved

    Time frame: Up to approximately 7 years

  13. Number of Patients With BCR::ABL Testing (per ELN Guidelines) Tested in 3-Month Intervals After Initiation of 2L Until BCR::ABL1 ≤0.1% was Achieved and Tested Every 12 Months Until CCyR was Achieved

    Time frame: Up to approximately 7 years

  14. Number of BCR::ABL Tests (per ELN Guidelines) After Initiation of 1L and 2L TKI Treatment Until BCR::ABL1 ≤0.1% was Achieved

    Time frame: Up to approximately 7 years

  15. Number of BCR::ABL Tests (per ELN Guidelines) After Initiation of 1L and 2L TKI Treatment Until CCyR was Achieved

    Time frame: Up to approximately 7 years

  16. Number of Molecular Testing by Year Following Initiation of 1L TKI Treatment During Which the T315I Mutation was Identified

    Time frame: Up to approximately 7 years

  17. Number of Patients With T3151 Mutation Testing During 1L and 2L TKI Treatment

    Time frame: Up to approximately 7 years

07

Study locations

1 site
  • Novartis
    East Hanover, New Jersey 07936, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jan 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 28, 2026
StartActual
Feb 1, 2024
Primary completionActual
Jan 21, 2025
CompletionActual
Jan 21, 2025
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374120
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Feb 1, 2024
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Last update
Feb 2, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion